RxSightRXST
Market Cap: $2.1B
About: RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Employees: 374
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
466% more call options, than puts
Call options by funds: $4.25M | Put options by funds: $752K
155% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 20
75% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 7 (+3) [Q2]
21% more capital invested
Capital invested by funds: $1.64B [Q1] → $1.98B (+$345M) [Q2]
16% more funds holding
Funds holding: 195 [Q1] → 226 (+31) [Q2]
4% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 78
1.26% less ownership
Funds ownership: 85.74% [Q1] → 84.48% (-1.26%) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Needham David Saxon 37% 1-year accuracy 24 / 65 met price target | 25%upside $66 | Buy Maintained | 20 Aug 2024 |
Wells Fargo Larry Biegelsen 68% 1-year accuracy 25 / 37 met price target | 2%upside $54 | Overweight Maintained | 6 Aug 2024 |
Oppenheimer Steven Lichtman 72% 1-year accuracy 13 / 18 met price target | 23%upside $65 | Outperform Maintained | 6 Aug 2024 |
Stifel Thomas Stephan 63% 1-year accuracy 12 / 19 met price target | 23%upside $65 | Buy Maintained | 6 Aug 2024 |
Needham David Saxon 37% 1-year accuracy 24 / 65 met price target | 2%upside $54 | Buy Maintained | 6 Aug 2024 |
Financial journalist opinion
Based on 3 articles about RXST published over the past 30 days